Diabetes Dialogue: ADA 2023 Recap

Published on: 

After a whirlwind conference packed with special episodes and late-breaking data, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, sit down to discuss their top takeaways from ADA 2023.

As the meeting does every year, the 83rd Scientific Session of the American Diabetes Association (ADA 2023) served as a showcase for the latest advancements in the management of diabetes. This year’s meeting brought forth groundbreaking research on multiple fronts, from pharmacologic therapies to diabetes technology and everything in between presented by leading experts in the field.

All told, the conference included more than 250 late-breaking abstracts, hundreds of poster presentations, and a slew of other sessions bringing forth insight from the current and future leaders in endocrinology, including hosts of HCPLive Endocrinology’s flagship podcast Diabetes Dialogue: Technology, Therapeutics, and Real-World Perspectives, Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center.

While on-site in San Diego, Isaacs chaired an interactive session examining case reports titled “Optimizing Diabetes Technology in Special Populations” and Bellini led an interactive presentation on titled “Steroids, Sick Days, and Stress” in a session titled “AID Systems—Which Setting Would you change”. In addition to their official conference duties, the hosts also sat down with 10 experts to record 9 on-site episodes of Diabetes Dialogue. Following the completion of the meeting, our hosts took a week to assess the mountains of data across a myriad of subjects covered at the meeting and recorded a 10th ADA 2023 episode with their top takeaways and highlight from the meeting.

Relevant disclosures for Dr. Isaacs include Eli Lilly and Company, Novo Nordisk, Sanofi, Abbott Diabetes Care, Dexcom, Medtronic, and others. Relevant disclosures for Dr. Bellini include Abbott Diabetes Care, MannKind, Provention Bio, and others.